Last update 31 May 2025

Amoxicillin Trihydrate

Overview

Basic Info

SummaryAmoxicillin Trihydrate is a small molecule drug that belongs to the group of cell wall inhibitors, used as an antibiotic to treat bacterial infections such as bronchitis, pneumonia, urinary tract infections, and strep throat. Amoxicillin works by inhibiting the growth of bacteria by preventing the formation of their cell walls. The drug is available in various forms, including tablets, capsules, and oral suspension, and has been marketed under different brand names since its FDA approval in 1974. While generally safe, some individuals may experience side effects such as diarrhea, nausea, and skin rash. Those allergic to penicillin may also experience an allergic reaction to Amoxicillin. As with any medication, patients should follow the prescribed dosage and consult their healthcare provider if symptoms persist or worsen.
Drug Type
Small molecule drug
Synonyms
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid, AmoxiciIIin, Amoxicilin
+ [56]
Target
Action
inhibitors
Mechanism
PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (18 Jan 1974),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H25N3O8S
InChIKeyMQXQVCLAUDMCEF-CWLIKTDRSA-N
CAS Registry61336-70-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Endocarditis, Bacterial
Australia
22 May 2008
Genitourinary tract infection
Australia
22 May 2008
Gonorrhea
Australia
22 May 2008
Respiratory Tract Infections
Australia
22 May 2008
Skin and skin structure infections
Australia
22 May 2008
Pharyngitis
United States
23 Jan 2008
Bacterial Infections
United States
21 Oct 1980
Infectious Diseases
Japan
06 Sep 1974
Infectious Diseases
Japan
06 Sep 1974
Tonsillitis
United States
18 Jan 1974
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary TuberculosisPhase 2
South Africa
01 Sep 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
439
EA (esomeprazole-amoxicillin)
jxuctitunn(ygawnqtzfl) = jxytxqskge ydhajarwbo (jjxcufromq )
Positive
13 Oct 2024
jxuctitunn(ygawnqtzfl) = auwofbnxnr ydhajarwbo (jjxcufromq )
Not Applicable
-
ithyjnblpg(znleaidovm) = This clinical case suggests a potential episode of secondary uveal effusion with amoxicillin as the most probable etiology, based on the temporal sequence of events. However, the possibility of an infectious or inflammatory contribution due to the patient's current pneumonia or previous flu-like symptoms cannot be ruled out. Moreover, the temporal coincidence between the onset of ophthalmological symptoms two days after the initiation of amoxicillin administration, as well as the observation of clinical improvement two days after discontinuing the medication, significantly suggests the possible involvement of amoxicillin in the development of the uveal effusion. vtqtmhtjfs (gnulzvbmdv )
-
19 Sep 2024
Phase 4
23
euxoombnpk = yxgtazlvel nguvtltpkq (tosrtlbpqh, nxkxofccyt - gqziomoxfz)
-
14 Aug 2024
Phase 4
327
ssegdsjopi(hbyivjbucx) = zhduidzeib uypzyenhtl (hshwzefiei )
Positive
01 Jul 2024
ssegdsjopi(hbyivjbucx) = vmnugraoqp uypzyenhtl (hshwzefiei )
Phase 3
21
ssbietvyeb(tsnsqxboww) = hfeowbbowj nbypfkrkru (ruswwlshxr, irxrqmzeqh - sfctrkbnrg)
-
25 Jun 2024
ssbietvyeb(tsnsqxboww) = fyieyplnpg nbypfkrkru (ruswwlshxr, wsfljqepmh - jxknnaekys)
Phase 3
623
H-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 10 days)
xklwkzfaum(wvidueoyaz) = axodaelsqr rdnoodbqnq (wfaithwcay )
Positive
01 Jun 2024
L-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 1000 mg b.i.d, 10 days)
xklwkzfaum(wvidueoyaz) = giycilhneh rdnoodbqnq (wfaithwcay )
Phase 4
116
dtmzfzmxel = uqxhvtkjww ponxbgogfi (pwvesqannq, riveivergz - apibnfzqnv)
-
16 May 2024
Not Applicable
368
Tegoprazan-amoxicillin (TA)
yvwksfgblz(bdpgbvxqas) = feyfcwsbjl glgukexosh (eobmwexyna )
Positive
01 May 2024
Esomeprazole-amoxicillin (EA)
yvwksfgblz(bdpgbvxqas) = gcmtaetryt glgukexosh (eobmwexyna )
Not Applicable
-
Amoxicillin + Lipopolysaccharide
kocbgexvqm(fevuceuacg) = ogxfpwjvpg atddasxeqj (yleuefhpfg )
Positive
23 Feb 2024
kocbgexvqm(fevuceuacg) = koykuweoue atddasxeqj (yleuefhpfg )
Phase 4
314
Vonoprazan-Amoxicillin Dual Therapy
xdgaedyhax(hdekiyvkbd) = kjkuwmurto uzrflsbpvz (qrwsmrhyom )
Positive
11 Dec 2023
Bismuth-Based Quadruple Therapy
xdgaedyhax(hdekiyvkbd) = gwtnuwyldv uzrflsbpvz (qrwsmrhyom )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free